Lunai Bioworks Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 01 May 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 12 Feb 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 30 Oct 2025 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 29 Sep 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →Lunai Bioworks Inc. — Overview & Financial Snapshot
Lunai Bioworks Inc. (NasdaqCM: LNAI) is a Healthcare company, ranked #6,361 of 6,774 companies globally and #3,636 of 4,000 in United States on PositoAI, with a Positivity Score of -17,466. Its market capitalisation is ₹20.11 Cr ($2.13M), P/E ratio is -0.4 and P/B ratio is -0.22. It currently has 3 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 4/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →